

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648EML

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	7	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	8	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	9	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	10	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	11	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	12	OCT 19	E-mail format enhanced
NEWS	13	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	14	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	15	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	16	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	17	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	18	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	19	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	20	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	21	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	22	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	23	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	24	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	25	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	26	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	27	DEC 18	CA/CAplus patent kind codes updated
NEWS	28	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	29	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	30	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS	EXPRESS		NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	LOGIN		Welcome Banner and News Items
NEWS	IPC8		For general information regarding STN implementation of IPC 8

NEWS X25        X.25 communication option no longer available  
NEWS PRICE     STN 2007 Prices

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:39:48 ON 29 DEC 2006

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:40:26 ON 29 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2006 HIGHEST RN 916479-39-5

DICTIONARY FILE UPDATES: 28 DEC 2006 HIGHEST RN 916479-39-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E

"N-(4-(3-(4-AMINOPHENYL)-4-ISOAZOLYL)PHENYL)-N'-(1-(4-FLUOROPHENYL)ETHYL)THIOUREA"/CN  
25

E1                    1

N-(4-(3-(4-(MORPHOLIN-4-YL)QUINOLIN-3-YL)ACRYLOYL)PHENYL)OXALAMIC ACID ETHYL  
ESTER/CN

E2                    1

N-(4-(3-(4-ACETYLPYPERAZIN-1-YL)PROPOXY)NAPHTHALEN-1-YL)-3-FLUORO-5-(PIPERIDIN-1-YL)  
BENZAMIDE/CN

E3                    0 -->

N-(4-(3-(4-AMINOPHENYL)-4-ISOAZOLYL)PHENYL)-N'-(1-(4-FLUOROPHENYL)ETHYL)THIOUREA/CN

E4                    1        N-(4-(3-(4-AMINOPHENYL)PROPYL)-1,3-THIAZOL-2-YL)ACETAMIDE/CN

E5                    1

N-(4-(3-(4-BENZYLPIPERIDIN-1-YL)PROPYL)PHENYL)-N-(4-HYDROXYBENZYL)BENZENESULFONAMIDE  
/CN

E6                    1

N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL)  
)ACETAMIDE/CN

E7 1  
 N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL)  
 )ACETAMIDE ACETATE/CN  
 E8 1  
 N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE/CN  
 E9 1  
 N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE  
 ACETATE/CN  
 E10 1  
 N-(4-(3-(4-CHLOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC  
 ACID/CN  
 E11 1  
 N-(4-(3-(4-CHLOROBENZYL CARBAMOYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID  
 ETHYL ESTER/CN  
 E12 1  
 N-(4-(3-(4-CHLOROPHENOXY)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN  
 E13 1  
 N-(4-(3-(4-CHLOROPHENYL)-1-OXO-2-PROPENYL) PHENYL)-2-METHYL-5-NITROBENZENESULFONAMIDE  
 /CN  
 E14 1  
 N-(4-(3-(4-CHLOROPHENYL) BENZO(C) ISOXAZOL-5-YL) PYRIMIDIN-2-YL) ACETAMIDE/CN  
 E15 1  
 N-(4-(3-(4-CHLOROPHENYL) ISOXAZOL-5-YL) THIAZOL-2-YL)-N-(3-(MORPHOLIN-4-YL) PROPYL) THIO  
 PHENE-2-CARBOXAMIDE/CN  
 E16 1  
 N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-  
 YL) PHENYL) ACETAMIDE/CN  
 E17 1  
 N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-  
 YL) PHENYL) METHANESULFONAMIDE/CN  
 E18 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-2-MORPHOLIN-  
 4-YL-2-OXOACETAMIDE/CN  
 E19 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-(2-METHOX  
 YETHYL) OXALAMIDE/CN  
 E20 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-ISOPROPYL  
 OXALAMIDE/CN  
 E21 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-PROPYLOXA  
 LAMIDE/CN  
 E22 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) MALONAMIC  
 ACID/CN  
 E23 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXALAMIDE/CN  
 E24 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC  
 ACID/CN  
 E25 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID  
 ETHYL ESTER/CN

=>

=> E

"N-(4-(3-(4-AMINOPHENYL)-4-ISOXAZOLYL) PHENYL)-N'-(1-(4-FLUOROPHENYL) ETHYL) THIOUREA"/  
 CN 25

E1 1 N-(4-(3-(4-(MORPHOLIN-4-YL) QUINOLIN-3-YL) ACRYLOYL) PHENYL) OXA  
 LAMIC ACID ETHYL ESTER/CN  
 E2 1 N-(4-(3-(4-ACETYLPIPERAZIN-1-YL) PROPOXY) NAPHTHALEN-1-YL)-3-F  
 LUORO-5-(PIPERIDIN-1-YL) BENZAMIDE/CN  
 E3 0 --> N-(4-(3-(4-AMINOPHENYL)-4-ISOXAZOLYL) PHENYL)-N'-(1-(4-FLURO  
 PHENYL) ETHYL) THIOUREA/CN

E4	1	N-(4-(3-(4-AMINOPHENYL) PROPYL)-1,3-THIAZOL-2-YL) ACETAMIDE/CN
E5	1	N-(4-(3-(4-BENZYLPIPERIDIN-1-YL) PROPYL) PHENYL)-N-(4-HYDROXYBENZYL) BENZENESULFONAMIDE/CN
E6	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL) ACETAMIDE/CN
E7	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL) ACETAMIDE ACETATE/CN
E8	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE/CN
E9	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE ACETATE/CN
E10	1	N-(4-(3-(4-CHLOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN
E11	1	N-(4-(3-(4-CHLOROBENZYL CARBAMOYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID ETHYL ESTER/CN
E12	1	N-(4-(3-(4-CHLOROPHENOXY)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN
E13	1	N-(4-(3-(4-CHLOROPHENYL)-1-OXO-2-PROPENYL) PHENYL)-2-METHYL-5-NITROBENZENESULFONAMIDE/CN
E14	1	N-(4-(3-(4-CHLOROPHENYL) BENZO(C) ISOXAZOL-5-YL) PYRIMIDIN-2-YL) ACETAMIDE/CN
E15	1	N-(4-(3-(4-CHLOROPHENYL) ISOXAZOL-5-YL) THIAZOL-2-YL)-N-(3-(MORPHOLIN-4-YL) PROPYL) THIOPHENE-2-CARBOXAMIDE/CN
E16	1	N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL) PHENYL) ACETAMIDE/CN
E17	1	N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL) PHENYL) METHANESULFONAMIDE/CN
E18	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-2-MORPHOLIN-4-YL-2-OXOACETAMIDE/CN
E19	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-(2-METHOXYETHYL) OXALAMIDE/CN
E20	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-ISOPROPYLOXALAMIDE/CN
E21	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-PROPYLOXALAMIDE/CN
E22	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) MALONAMIC ACID/CN
E23	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXALAMIDE/CN
E24	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN
E25	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID ETHYL ESTER/CN

=> E

"N1-(4-(3-(4-AMINOPHENYL)-4-ISOXAZOLYL) PHENYL)-N2-(1-(4-FLUOROPHENYL) ETHYL) THIOUREA"/CN 25

E1	1	N1-(4-(2,4-DIMETHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL)-4-METHOXY-N3, N3-DIMETHYLBENZENE-1,3-DIAMINE/CN
E2	1	N1-(4-(2-(4-FLUOROPHENYL)-6-TRIFLUOROMETHYLPYRAZOLO(1,5-A) PYRIDIN-3-YL) PYRIMIDIN-2-YL)-N3, N3-DIMETHYLPROPANE-1,3-DIAMINE/CN
E3	0 -->	N1-(4-(3-(4-AMINOPHENYL)-4-ISOXAZOLYL) PHENYL)-N2-(1-(4-FLUOROPHENYL) ETHYL) THIOUREA/CN
E4	1	N1-(4-(3-BROMO-4-((2,4-DIFLUOROBENZYL) OXY)-6-METHYL-2-OXO-2H-PYRIDIN-1-YL) BENZYL)-L-SERINAMIDE HYDROCHLORIDE/CN
E5	1	N1-(4-(3-METHYLCARBAMOYL-4-METHYL-7,8-METHYLENEDIOXY-3,4-DIHYDRO-5H-2,3-BENZODIAZEPIN-1-YL) PHENYL)-N3-METHYLUREA/CN
E6	1	N1-(4-(4-AMINO-7-(4-OXOCYCLOHEXYL)-7H-PYRROLO(2,3-D) PYRIMIDIN-5-YL)-2-FLUOROPHENYL)-2,3-DICHLORO-1-BENZENESULFONAMIDE/CN
E7	1	N1-(4-(4-AMINO-7-(8-METHYL-8-AZA(3.2.1) BICYCLOOCTAN-3-YL)-7H-PYRROLO(2,3-D) PYRIMIDIN-5-YL)-2-FLUOROPHENYL)-2,3-DICHLORO-1-BENZENESULFONAMIDE/CN
E8	1	N1-(4-(4-CHLOROPHENOXY) PHENYL)-N,N-DIMETHYLUREA/CN

E9	1	N1-(4-(DIHEXYLAMINO) PHENYL)-N1,N4,N4-TRIHEXYL-1,4-PHENYLENEDIAMINE/CN
E10	1	N1-(4-AMINOBTYL)-N4,N4-BIS(2-HYDROXYETHYL)-2-NITRO-P-PHENYLENEDIAMINE/CN
E11	1	N1-(4-BROMO-2-((2-FLUOROPHENYL) CARBONYL) PHENYL)-L-ALANINAMIDE/CN
E12	1	N1-(4-BROMO-2-((2-FLUOROPHENYL) CARBONYL) PHENYL) GLYCINAMIDE/CN
E13	1	N1-(4-BROMOBENZYL)-N1-(PYRID-2-YL) BUTANE-1,4-DIAMINE/CN
E14	1	N1-(4-BROMOPHENYL)-N2-HYDROXY-2-OXO-2-PHENYLACETAMIDINE/CN
E15	1	N1-(4-BUTOXYBENZYL)-5,6-DIHYDROTHIOURACIL/CN
E16	1	N1-(4-CHLOROBENZYL)-4-(3-FLUORO-1-PIPERIDINYL)-4-OXO-1,3-(S)-BUTANEDIAMINE BIS(TRIFLUOROACETATE)/CN
E17	1	N1-(4-CHLOROPHENYL)-N3-CYANOQUANIDINE/CN
E18	1	N1-(4-IMINO-1,3-DIMETHYL-2,6-DIOXOHEXAHYDROPYRIMIDIN-5-YL) SULFANILAMIDE/CN
E19	1	N1-(4-ISOPROPENYLPHENYL)-N3,N3-DIMETHYLSEMICARBAZIDE/CN
E20	1	N1-(4-ISOPROPOXYBENZOYL)-P-AMINOBENZENESULFONAMIDE/CN
E21	1	N1-(4-ISOPROPOXYBENZOYL) SULFANILAMIDE/CN
E22	1	N1-(4-METHYL-2-PYRIDYL) SULFANILAMIDE SODIUM/CN
E23	1	N1-(4-METHYL-2-PYRIDYL-6-TRIFLUOROMETHYL) SULFANILAMIDE/CN
E24	1	N1-(4-METHYL-2-PYRIMIDINYL) SULFANILAMIDE/CN
E25	1	N1-(4-METHYL-2-THIAZOLYL) SULFANILAMIDE/CN

=> E

"N-(4-(3-(4-AMINOPHENYL)-4-ISOXAZOLYL) PHENYL)-N-(1-(4-FLUOROPHENYL) ETHYL) THIOUREA"/CN 25

E1	1	N-(4-(3-(4-(MORPHOLIN-4-YL) QUINOLIN-3-YL) ACRYLOYL) PHENYL) OXALAMIC ACID ETHYL ESTER/CN
E2	1	N-(4-(3-(4-ACETYLPIPERAZIN-1-YL) PROPOXY) NAPHTHALEN-1-YL)-3-FLUORO-5-(PIPERIDIN-1-YL) BENZAMIDE/CN
E3	0 -->	N-(4-(3-(4-AMINOPHENYL)-4-ISOXAZOLYL) PHENYL)-N-(1-(4-FLUOROPHENYL) ETHYL) THIOUREA/CN
E4	1	N-(4-(3-(4-AMINOPHENYL) PROPYL)-1,3-THIAZOL-2-YL) ACETAMIDE/CN
E5	1	N-(4-(3-(4-BENZYLPIPERIDIN-1-YL) PROPYL) PHENYL)-N-(4-HYDROXYBENZYL) BENZENESULFONAMIDE/CN
E6	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL) ACETAMIDE/CN
E7	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL) ACETAMIDE ACETATE/CN
E8	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE/CN
E9	1	N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE ACETATE/CN
E10	1	N-(4-(3-(4-CHLOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN
E11	1	N-(4-(3-(4-CHLOROBENZYL CARBAMOYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID ETHYL ESTER/CN
E12	1	N-(4-(3-(4-CHLOROPHENOXY)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN
E13	1	N-(4-(3-(4-CHLOROPHENYL)-1-OXO-2-PROPENYL) PHENYL)-2-METHYL-5-NITROBENZENESULFONAMIDE/CN
E14	1	N-(4-(3-(4-CHLOROPHENYL) BENZO(C) ISOXAZOL-5-YL) PYRIMIDIN-2-YL) ACETAMIDE/CN
E15	1	N-(4-(3-(4-CHLOROPHENYL) ISOXAZOL-5-YL) THIAZOL-2-YL)-N-(3-(MORPHOLIN-4-YL) PROPYL) THIOPHENE-2-CARBOXAMIDE/CN
E16	1	N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL) PHENYL) ACETAMIDE/CN
E17	1	N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL) PHENYL) METHANESULFONAMIDE/CN
E18	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-2-MORPHOLIN-4-YL-2-OXOACETAMIDE/CN
E19	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-(2-METHOXYETHYL) OXALAMIDE/CN

E20	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-ISOPROPYLOXALAMIDE/CN
E21	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-PROPYLOXALAMIDE/CN
E22	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)MALONAMIC ACID/CN
E23	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)OXALAMIDE/CN
E24	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)OXAMIC ACID/CN
E25	1	N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)OXAMIC ACID ETHYL ESTER/CN

=>

Uploading C:\Program Files\Stnexp\Queries\thiourea.str

L1        STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 19:25:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -            0 TO ITERATE

100.0% PROCESSED	0 ITERATIONS	0 ANSWERS
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	0 TO	0
PROJECTED ANSWERS:	0 TO	0

L2            0 SEA SSS SAM L1

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648EML

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 21 CA/CAplus fields enhanced with simultaneous left and right  
truncation  
NEWS 7 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 8 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 9 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 10 SEP 28 CEABA-VTB classification code fields reloaded with new  
classification scheme  
NEWS 11 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 12 OCT 19 E-mail format enhanced  
NEWS 13 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 14 OCT 23 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 15 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 16 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 17 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 18 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 19 NOV 10 STN Express with Discover! free maintenance release Version  
8.01c now available  
NEWS 20 NOV 20 CAS Registry Number crossover limit increased to 300,000 in  
additional databases  
NEWS 21 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased  
to 50,000  
NEWS 22 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 23 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 24 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 25 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and  
functionality  
NEWS 26 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced  
with preparation role  
NEWS 27 DEC 18 CA/CAplus patent kind codes updated  
NEWS 28 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased  
to 50,000  
NEWS 29 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 30 DEC 27 CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS X25        X.25 communication option no longer available  
NEWS PRICE     STN 2007 Prices

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:39:48 ON 29 DEC 2006

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:40:26 ON 29 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2006 HIGHEST RN 916479-39-5

DICTIONARY FILE UPDATES: 28 DEC 2006 HIGHEST RN 916479-39-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E

"N-(4-(3-(4-AMINOPHENYL)-4-ISOAZOLYL)PHENYL)-N'-(1-(4-FLUOROPHENYL)ETHYL)THIOUREA"/CN  
25

E1                    1

N-(4-(3-(4-(MORPHOLIN-4-YL)QUINOLIN-3-YL)ACRYLOYL)PHENYL)OXALAMIC ACID ETHYL  
ESTER/CN

E2                    1

N-(4-(3-(4-ACETYLPYPERAZIN-1-YL)PROPOXY)NAPHTHALEN-1-YL)-3-FLUORO-5-(PIPERIDIN-1-YL)  
BENZAMIDE/CN

E3                    0 -->

N-(4-(3-(4-AMINOPHENYL)-4-ISOAZOLYL)PHENYL)-N'-(1-(4-FLUOROPHENYL)ETHYL)THIOUREA/CN

E4                    1        N-(4-(3-(4-AMINOPHENYL)PROPYL)-1,3-THIAZOL-2-YL)ACETAMIDE/CN

E5                    1

N-(4-(3-(4-BENZYLPIPERIDIN-1-YL)PROPYL)PHENYL)-N-(4-HYDROXYBENZYL)BENZENESULFONAMIDE  
/CN

E6                    1

N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL)  
)ACETAMIDE/CN




E7 1  
 N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY)-3-METHYLNAPHTHALEN-1-YL)  
 )ACETAMIDE ACETATE/CN  
 E8 1  
 N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE/CN  
 E9 1  
 N-(4-(3-(4-CARBAMIMIDOYLPHENYL)-2-OXOOXAZOLIDIN-5-YLMETHOXY) PHENYL) ACETAMIDE  
 ACETATE/CN  
 E10 1  
 N-(4-(3-(4-CHLOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC  
 ACID/CN  
 E11 1  
 N-(4-(3-(4-CHLOROBENZYL CARBAMOYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID  
 ETHYL ESTER/CN  
 E12 1  
 N-(4-(3-(4-CHLOROPHENOXY)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID/CN  
 E13 1  
 N-(4-(3-(4-CHLOROPHENYL)-1-OXO-2-PROPENYL) PHENYL)-2-METHYL-5-NITROBENZENESULFONAMIDE  
 /CN  
 E14 1  
 N-(4-(3-(4-CHLOROPHENYL) BENZO(C) ISOXAZOL-5-YL) PYRIMIDIN-2-YL) ACETAMIDE/CN  
 E15 1  
 N-(4-(3-(4-CHLOROPHENYL) ISOXAZOL-5-YL) THIAZOL-2-YL)-N-(3-(MORPHOLIN-4-YL) PROPYL) THIO  
 PHENE-2-CARBOXAMIDE/CN  
 E16 1  
 N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-  
 YL) PHENYL) ACETAMIDE/CN  
 E17 1  
 N-(4-(3-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-  
 YL) PHENYL) METHANESULFONAMIDE/CN  
 E18 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-2-MORPHOLIN-  
 4-YL-2-OXOACETAMIDE/CN  
 E19 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-(2-METHOX  
 YETHYL) OXALAMIDE/CN  
 E20 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-ISOPROPYL  
 OXALAMIDE/CN  
 E21 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL)-N'-PROPYLOXA  
 LAMIDE/CN  
 E22 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) MALONAMIC  
 ACID/CN  
 E23 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXALAMIDE/CN  
 E24 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC  
 ACID/CN  
 E25 1  
 N-(4-(3-(4-FLUOROBENZENESULFONYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) OXAMIC ACID  
 ETHYL ESTER/CN

L7 ANSWER 91 OF 177 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 736982-21-1 REGISTRY  
 ED Entered STN: 01 Sep 2004  
 CN Thiourea, N-[4-[3-(4-aminophenyl)-4-isoxazoly]phenyl]-N'-[1-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)  
 MF C24 H21 F N4 O S  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

# Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
C3NO	NOC3	15	C3NO	16.167.5	1
C6	C6	16	C6	46.150.18	3

PAGE 1-A



PAGE 2-A

F

Experimental Property Tags (ETAG)

PROPERTY | NOTE  
 =====+=====

Mass Spectral | (1) CAS

(1) ~~Bloom, Jonathan David~~; US 2004157900 A1 2004 CAPLUS

Predicted Properties (PPROP)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	1.0	pH 1 25 deg C	(1)
Bioconc. Factor (BCF)	10.28	pH 2 25 deg C	(1)
Bioconc. Factor (BCF)	53.90	pH 3 25 deg C	(1)
Bioconc. Factor (BCF)	90.90	pH 4 25 deg C	(1)
Bioconc. Factor (BCF)	97.57	pH 5 25 deg C	(1)
Bioconc. Factor (BCF)	98.29	pH 6 25 deg C	(1)
Bioconc. Factor (BCF)	98.36	pH 7 25 deg C	(1)
Bioconc. Factor (BCF)	98.36	pH 8 25 deg C	(1)
Bioconc. Factor (BCF)	98.26	pH 9 25 deg C	(1)
Bioconc. Factor (BCF)	97.29	pH 10 25 deg C	(1)
Boiling Point (BP)	583.4+/-60.0 deg C	760 Torr	(1)
Density (DEN)	1.309+/-0.06 g/cm**3	760 Torr	(1)
Enthalpy of Vap. (HVAP)	87.20+/-3.0 kJ/mol	760 Torr	(1)
Flash Point (FP)	306.6+/-32.9 deg C		(1)
Freely Rotatable Bonds (FRB)	6		(1)
H acceptors (HAC)	5		(1)
H donors (HD)	4		(1)
Hydrogen Donors/Acceptors Sum (HDAS)	9		(1)
Koc (KOC)	8.42	pH 1 25 deg C	(1)
Koc (KOC)	97.08	pH 2 25 deg C	(1)
Koc (KOC)	508.80	pH 3 25 deg C	(1)
Koc (KOC)	858.08	pH 4 25 deg C	(1)
Koc (KOC)	921.04	pH 5 25 deg C	(1)
Koc (KOC)	927.84	pH 6 25 deg C	(1)
Koc (KOC)	928.52	pH 7 25 deg C	(1)
Koc (KOC)	928.49	pH 8 25 deg C	(1)
Koc (KOC)	927.58	pH 9 25 deg C	(1)
Koc (KOC)	918.43	pH 10 25 deg C	(1)
LOGD (LOGD)	0.88	pH 1 25 deg C	(1)
LOGD (LOGD)	1.94	pH 2 25 deg C	(1)
LOGD (LOGD)	2.66	pH 3 25 deg C	(1)
LOGD (LOGD)	2.89	pH 4 25 deg C	(1)
LOGD (LOGD)	2.92	pH 5 25 deg C	(1)
LOGD (LOGD)	2.92	pH 6 25 deg C	(1)
LOGD (LOGD)	2.92	pH 7 25 deg C	(1)
LOGD (LOGD)	2.92	pH 8 25 deg C	(1)
LOGD (LOGD)	2.92	pH 9 25 deg C	(1)
LOGD (LOGD)	2.92	pH 10 25 deg C	(1)
LOGP (LOGP)	2.925+/-0.555	25 deg C	(1)
Mass Intrinsic Solubility (SLB.MASS)	0.0069 g/L	25 deg C	(1)
Mass Solubility (SLB.MASS)	0.78 g/L	pH 1 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.069 g/L	pH 2 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.013 g/L	pH 3 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0078 g/L	pH 4 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0074 g/L	pH 5 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0069 g/L	pH 6 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0069 g/L	pH 7 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0069 g/L	pH 8 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0069 g/L	pH 9 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0074 g/L	pH 10 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0069 g/L	Unbuffered Water	(1)

Molar Intrinsic Solubility (ISLB.MOL)	0.000016 mol/L	pH 7.00 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.0018 mol/L	pH 1 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.00016 mol/L	pH 2 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000030 mol/L	pH 3 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000018 mol/L	pH 4 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000017 mol/L	pH 5 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000016 mol/L	pH 6 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000016 mol/L	pH 7 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000016 mol/L	pH 8 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000016 mol/L	pH 9 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000017 mol/L	pH 10 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000016 mol/L	Unbuffered Water	(1)
Molar Volume (MVOL)	330.2+/-3.0 cm**3/mol	pH 7.00 25 deg C 20 deg C 760 Torr	(1)
Molecular Weight (MW)	432.51		(1)
PKA (PKA)	12.00+/-0.70	Most Acidic 25 deg C	(1)
PKA (PKA)	2.91+/-0.10	Most Basic 25 deg C	(1)
Polar Surface Area (PSA)	108.20 A**2		(1)
Vapor Pressure (VP)	1.34E-13 Torr	25 deg C	(1)

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.19  
((C) 1994-2007 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

#### REFERENCE 1




AN 141:190783 CA  
 TI Preparation of isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus  
 IN Bloom, Jonathan David  
 PA Wyeth Holdings Corporation, USA  
 SO U.S. Pat. Appl. Publ., 9 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM C07D261-02  
 ICS A61K031-42  
 NCL 514378000  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157900	A1	20040812	US 2004-772799	20040205
	WO 2004072052	A2	20040826	WO 2004-US3725	20040209
	WO 2004072052	A3	20041111		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KP, KP, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-446602P 20030211  
 GI



AB The title compds. [I; R1 = halo, H; R2 = alkyl; X = II, III; R3 = alkyl, cycloalkyl, hydroxymethyl, etc.; R4 = alkyl which may be further substituted with (un)substituted Ph, cycloalkyl, pyridyl, etc.], useful for inhibiting replication of a herpes virus, were prepared E.g., a multi-step synthesis of 1-[4-(4-benzylisoxazol-3-yl)phenyl]-3-[1-(4-fluorophenyl)ethyl]thiourea (IV), was given. Seventeen title compds. I were prepared as described for IV, and tested for activity as herpes virus inhibitors (IC50 values against VZV, MTS, CMV, HSV and RSV were given).

ST isoxazolyphenyl benzyl thiourea prepn antiviral herpes virus; varicella zoster virus isoxazolyphenyl benzyl thiourea prepn

IT Antiviral agents  
 Human  
 Human herpesvirus  
 Human herpesvirus 3  
 Human herpesvirus 5  
 (preparation of isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus)

IT Infection  
 (viral; preparation of isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus)

IT 736982-12-0P 736982-13-1P 736982-14-2P 736982-15-3P 736982-16-4P  
 736982-17-5P 736982-18-6P 736982-19-7P 736982-20-0P 736982-21-1P  
 736982-22-2P 736982-23-3P 736982-24-4P 736982-25-5P 736982-26-6P  
 736982-27-7P 736982-28-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus)

IT 100-10-7, 4-(Dimethylamino)benzaldehyde 623-04-1, 4-Aminobenzyl alcohol  
 10147-11-2, 3-Phenyl-1-propyne 14235-81-5, 4-Ethynylaniline 182565-27-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of isoxazole-containing thiourea inhibitors useful for treatment of

varicella zoster virus)

IT 2929-84-2P, 4-Dimethylaminobenzaldehyde oxime 144072-29-7P  
144072-30-0P 157991-82-7P 170727-03-4P 190446-52-7P 736982-09-5P  
736982-10-8P 736982-11-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of isoxazole-containing thiourea inhibitors useful for treatment of

varicella zoster virus)